The 3rd Inflammasome Therapeutics Summit returns as the definitive industry-dedicated forum, bringing you the latest discoveries, preclinical, translational and early clinical developments on novel inflammasome-targetted therapeutics.

The three days meeting will have two parallel tracks of learning on the molecular mechanisms of inflammasome signalling, digging into inflammasome formation to identify novel drug targets and optimise drug binding, leveraging inflammasome biomarkers in the translational and early clinical setting, as well as mapping out therapeutic applications across monogenic diseases, in super-acute settings such as infectious lung diseases, in rapidly progressing diseases like NASH, GI diseases, through to chronic conditions such as cancer and neurodegeneration.

Brought direct to your home office with a jam-packed agenda and online virtual networking opportunities, this summit will delve into the fundamental biology of inflammasome signalling to identify and clinically validate novel drug targets.

Join us on our dedicated virtual platform as we unite drug developers and researchers in accelerating novel inflammasome therapeutics into proof-of-concept clinical trials and beyond!